261 related articles for article (PubMed ID: 32507936)
1. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of familial adenomatous polyposis.
Lynch PM
Fam Cancer; 2016 Jul; 15(3):467-75. PubMed ID: 27083160
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
6. Updated Perspectives on the Diagnosis and Management of Familial Adenomatous Polyposis.
Kyriakidis F; Kogias D; Venou TM; Karlafti E; Paramythiotis D
Appl Clin Genet; 2023; 16():139-153. PubMed ID: 37600856
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention in familial adenomatous polyposis.
Kim B; Giardiello FM
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
[TBL] [Abstract][Full Text] [Related]
9. [Chemoprevention for Familial Adenomatous Polyposis].
Matsubara N; Tamura K; Tomita N
Gan To Kagaku Ryoho; 2015 Jun; 42(6):699-703. PubMed ID: 26199240
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal neoplasia.
Wakeman C; Keenan J; Eteuati J; Hollington P; Eglinton T; Frizelle F
ANZ J Surg; 2017 Dec; 87(12):E228-E232. PubMed ID: 26686322
[TBL] [Abstract][Full Text] [Related]
11. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and familial adenomatous polyposis: coming full circle.
Chan AT
Cancer Prev Res (Phila); 2011 May; 4(5):623-7. PubMed ID: 21543340
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Manzano A; Pérez-Segura P
ScientificWorldJournal; 2012; 2012():327341. PubMed ID: 22649288
[TBL] [Abstract][Full Text] [Related]
14. [Familial adenomatous polyposis (FAP)--diagnosis and management].
Gondo N; Nakagawa K; Yanagi H; Yamamura T
Gan To Kagaku Ryoho; 2002 Apr; 29(4):532-8. PubMed ID: 11977536
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of carcinogenesis in familial tumors.
Ishikawa H
Int J Clin Oncol; 2004 Aug; 9(4):299-303. PubMed ID: 15375706
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK; Mehta NA; Singh H; El-Matary W; Bernstein CN
Fam Cancer; 2023 Oct; 22(4):413-422. PubMed ID: 37119510
[TBL] [Abstract][Full Text] [Related]
17. Familial adenomatous polyposis.
Half E; Bercovich D; Rozen P
Orphanet J Rare Dis; 2009 Oct; 4():22. PubMed ID: 19822006
[TBL] [Abstract][Full Text] [Related]
18. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
